Primary source: Report of the ICH Technology Task Force
ICH E6(R3) Annex 2 was adopted at Step 4, transitioning to the implementation phase, necessitating changes in safety monitoring practices for clinical trials.
The adoption of this guideline reflects a significant shift towards integrating decentralized trial methods and RWD in clinical research, enhancing patient safety and data relevance.
MAHs and trial sponsors must align their safety monitoring and data collection workflows with the new GCP principles established in ICH E6(R3) Annex 2.
Regulatory Intelligence Lead
Ongoing review recommended as further guidance from ICH may emerge during the implementation phase.
Finalization and Step 4 adoption of ICH E6(R3) Annex 2; transition to implementation phase for new GCP principles applied to various trial designs and data sources.
Significant impact on clinical trial safety operations; MAH and sponsors must align safety monitoring and data collection processes with the new Annex 2 requirements for decentralized and RWD-integrated trials.
Increased collaboration security and data confidentiality during guideline development
Introduction of secure sharing protocols
Facilitates regulatory convergence and promotes consistency in assessment across regions.
Enhanced data sharing processes
MAHs and trial sponsors must align their safety monitoring and data collection workflows with the new GCP principles established in ICH E6(R3) Annex 2.
The ICH Assembly adopted ICH E6(R3) Annex 2, which introduces new GCP principles for decentralized trials and integration of real-world data (RWD) into safety monitoring processes. This guideline is set to enter the implementation phase, requiring MAH and sponsors to align their safety monitoring and data collection with these new requirements.
What changed: ICH E6(R3) Annex 2 was adopted at Step 4, transitioning to the implementation phase, necessitating changes in safety monitoring practices for clinical trials.
Why it matters: The adoption of this guideline reflects a significant shift towards integrating decentralized trial methods and RWD in clinical research, enhancing patient safety and data relevance.
Practical implication: MAHs and trial sponsors must align their safety monitoring and data collection workflows with the new GCP principles established in ICH E6(R3) Annex 2.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
